Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Bioplastics01:27

Bioplastics

Bioplastics derived from microbial processes present a sustainable alternative to conventional petroleum-based plastics. Among these, polyhydroxyalkanoates (PHAs), particularly polyhydroxybutyrates (PHBs), have emerged as prominent candidates due to their biodegradability and biocompatibility. These polymers are synthesized by a variety of bacteria, such as Cupriavidus necator and Pseudomonas putida, which naturally accumulate PHAs as intracellular carbon and energy reserves, especially under...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterizing Barriers to Living Donor Liver Transplantation for Pediatric Recipients: Qualitative Results from the SOCIAL-Tx Study.

The Journal of pediatrics·2026
Same author

Postvaccination Immunogenicity Among Pediatric Solid Organ Transplant Recipients.

JAMA pediatrics·2025
Same author

Liver abnormalities are frequent and persistent in patients with Fanconi anemia.

Blood advances·2024
Same author

Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients.

JAMA network open·2023
Same author

Immunosuppression-Free Life after Pediatric Liver Transplant: A Case-Control Study from the Society of Pediatric Liver Transplant (SPLIT) Registry.

The Journal of pediatrics·2023
Same author

Early allograft dysfunction in a pediatric liver allograft with an occult pathogenic mutation in the urea cycle.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2023

Related Experiment Video

Updated: Jul 12, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

PEGylated bioactive molecules in biodegradable polymer microparticles.

Paul G Schmidt1, Kathleen M Campbell, Kenneth D Hinds

  • 1PR Pharmaceuticals, Inc., Fort Collins, Colorado 80524, USA. pschmidt@prpharm.com

Expert Opinion on Biological Therapy
|August 31, 2007
PubMed
Summary

Combining poly(ethylene glycol) (PEG)ylation with microparticle encapsulation enhances the stability and effectiveness of peptide and oligonucleotide biotherapeutics for chronic diseases. This synergistic approach overcomes limitations of individual technologies, improving drug delivery and therapeutic outcomes.

More Related Videos

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Related Experiment Videos

Last Updated: Jul 12, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
12:48

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

Area of Science:

  • Biotechnology
  • Drug Delivery
  • Polymer Science

Background:

  • Injectable biotherapeutics like peptides and oligonucleotides show promise for chronic diseases but require formulation for stability and extended circulation.
  • Poly(ethylene glycol) (PEG)ylation increases circulation time and reduces degradation, while microparticle encapsulation provides sustained release, but each has limitations.
  • Existing PEGylated drugs and microencapsulated peptides have market presence, yet widespread use is hindered by individual technology drawbacks.

Purpose of the Study:

  • To explore the synergistic benefits of combining PEGylation and microparticle encapsulation for biotherapeutics.
  • To demonstrate how this combined approach addresses limitations of individual formulation strategies.
  • To review evidence supporting the synergy between PEGylation and microencapsulation using examples of protein, peptide, and oligonucleotide therapeutics.

Main Methods:

  • Review of existing research on the encapsulation of PEGylated bioactive molecules.
  • Analysis of how microencapsulation mitigates activity reduction and circulation limitations of PEGylated agents.
  • Examination of how PEGylated actives improve microparticle characteristics like chemical stability and drug content.

Main Results:

  • Combining PEGylation and microencapsulation offers synergistic advantages, overcoming individual technology limitations.
  • Microencapsulation can address issues with PEGylated agents, such as reduced activity and short circulation times, by using lower molecular weight PEG.
  • PEGylation of actives can improve microparticle formulations by reducing chemical degradation, burst release, and increasing drug loading.

Conclusions:

  • The combination of PEGylation and microparticle encapsulation presents a powerful strategy for enhancing biotherapeutic delivery.
  • This synergistic approach improves drug stability, circulation lifetime, and controlled release profiles.
  • The review highlights the successful application of this combined strategy with various biologics, including insulin and pegaptanib, demonstrating its broad therapeutic potential.